via Johns Hopkins University
Perhaps no region of the brain is more fittingly named than the claustrum, taken from the Latin word for “hidden or shut away.” The claustrum is an extremely thin sheet of neurons deep within the cortex, yet it reaches out to every other region of the brain. Its true purpose remains “hidden away” as well, with researchers speculating about many functions. For example, Francis Crick of DNA-discovery fame believed that the claustrum is the seat of consciousness, responsible for awareness and sense of self.
What is known is that this region contains a large number of receptors targeted by psychedelic drugs such as LSD or psilocybin ¾ the hallucinogenic chemical found in certain mushrooms. To see what happens in the claustrum when people are on psychedelics, Johns Hopkins Medicine researchers compared the brain scans of people after they took psilocybin with their scans after taking a placebo.
The scans after psilocybin use showed that the claustrum was less active, meaning the area of the brain believed responsible for setting attention and switching tasks is turned down when on the drug. The researchers say that this ties in with what people report as typical effects of psychedelic drugs, including feelings of being connected to everything and reduced senses of self or ego.
“Our findings move us one step closer to understanding mechanisms underlying how psilocybin works in the brain,” says Frederick Barrett, Ph.D., assistant professor of psychiatry and behavioral sciences at the Johns Hopkins University School of Medicine and a member of the school’s Center for Psychedelic and Consciousness Research. “This will hopefully enable us to better understand why it’s an effective therapy for certain psychiatric disorders, which might help us tailor therapies to help people more.”
Because of its deep-rooted location in the brain, the claustrum has been difficult to access and study. Last year, Barrett and his colleagues at the University of Maryland, Baltimore, developed a method to detect brain activity in the claustrum using functional magnetic resonance imaging (fMRI).
For this new study, the researchers used fMRI with 15 people and observed the claustrum brain region after the participants took either psilocybin or a placebo. They found that psilocybin reduced neural activity in the claustrum by 15% to 30%. This lowered activity also appeared to be associated with stronger subjective effects of the drug, such as emotional and mystical experiences. The researchers also found that psilocybin changed the way that the claustrum communicated with brain regions involved in hearing, attention, decision-making and remembering.
With the highly detailed imaging of the claustrum provided by fMRI, the researchers next hope to look at the mysterious brain region in people with certain psychiatric disorders such as depression and substance use disorder. The goal of these experiments will be to see what roles, if any, the claustrum plays in these conditions. The researchers also plan to observe the claustrum’s activity when under the influence of other psychedelics, such as salvinorin A, a hallucinogen derived from a Mexican plant.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
- Thomas Hartle: How psilocybin eased my cancer journeyon March 6, 2021 at 9:31 am
My name is Thomas Hartle and I am a Canadian who has been dealing with stage 4 colon cancer for the past five years.
- The Psilocybin Patent Race Is Onon March 6, 2021 at 1:30 am
It feels like these companies are casting a wide net, but it makes sense to file at the beginning of this mushroom mania.
- Successful Medical Applications of Psilocybin Help Erode Harmful Stigmason March 4, 2021 at 1:00 am
An example of a recent study includes data based on an examination of 27 people, which found that a treatment featuring the hallucinogen psilocybin worked better than the usual antidepressant ...
- Mydecine Exports Psilocybin Mushrooms From Jamaica To Canada — An Industry Firston March 2, 2021 at 5:46 pm
Psychedelics and biopharma company Mydecine (CSE: MYCO) (OTC: MYCOF) recently announced the successful export of 20 kilograms of dried psilocybin mushrooms from a cultivation facility in Jamaica to a ...
- With Psilocybin, Significant Progress is Being Made with Substance Use Disorderson March 2, 2021 at 1:21 am
Mental health support is not as strong as it should be for Canadians. At the moment, an overburdened system, structural gaps and ineffective medications with potential debilitating side effects can ...
Go deeper with Google Headlines on:
Go deeper with Bing News on:
- Psychedelics & Cannabis Have Triggered A Mad Dash In The Market & 1 Company Stands To Capitalizeon March 6, 2021 at 1:08 am
If I were to tell you six years ago that we'd have legal cannabis and psychedelic industries, you might think I ...
- Why mental health researchers are studying psychedelics all wrongon March 5, 2021 at 11:00 pm
Two psychedelic advocates say that the mental health-industrial complex is not equipped to study drugs like ketamine and MDMA ...
- Women and Men Self-Medicate With Psychedelics for Different Reasonson March 5, 2021 at 10:31 am
Research published today by The Global Drug Survey has shed light on the experiences of people taking psychedelics to aid their wellbeing and mental health. The online study, undertaken between ...
- More Women Than Men Self-Medicate With Psychedelics, Global Survey Suggestson March 5, 2021 at 7:36 am
Women are more likely than men to use LSD and magic mushrooms to treat psychiatric conditions and emotional distress, according to the results of the 2020 ...
- The Race to Patent Psychedelics Is Just Getting Startedon March 5, 2021 at 6:59 am
Psychedelics now appear in patent applications for Philip Morris e-cigarettes, periodontal disease, hair loss, weight loss, and food allergies.